199 related articles for article (PubMed ID: 11594292)
21. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Zenari L; Marangoni A
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
[TBL] [Abstract][Full Text] [Related]
22. Which patients should be evaluated for blood glucose variability?
Candido R
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():9-12. PubMed ID: 24034514
[TBL] [Abstract][Full Text] [Related]
23. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
24. Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?
Paul SK; Holman RR
Diabet Med; 2017 Sep; 34(9):1284-1290. PubMed ID: 28477414
[TBL] [Abstract][Full Text] [Related]
25. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Bellomo Damato A; Stefanelli G; Laviola L; Giorgino R; Giorgino F
Diabet Med; 2011 May; 28(5):560-6. PubMed ID: 21204958
[TBL] [Abstract][Full Text] [Related]
26. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
Cavalot F
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
[TBL] [Abstract][Full Text] [Related]
27. When basal insulin therapy in type 2 diabetes mellitus is not enough--what next?
Raccah D; Bretzel RG; Owens D; Riddle M
Diabetes Metab Res Rev; 2007 May; 23(4):257-64. PubMed ID: 17315242
[TBL] [Abstract][Full Text] [Related]
28. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
Siebenhofer A; Plank J; Berghold A; Narath M; Gfrerer R; Pieber TR
Cochrane Database Syst Rev; 2004 Oct; (4):CD003287. PubMed ID: 15495047
[TBL] [Abstract][Full Text] [Related]
29. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
Siebenhofer A; Plank J; Berghold A; Narath M; Gfrerer R; Pieber TR
Cochrane Database Syst Rev; 2004; (2):CD003287. PubMed ID: 15106199
[TBL] [Abstract][Full Text] [Related]
30. Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.
Umpierrez G; Pantalone KM; Atisso CM; Landó LF; Patel H
Diabetes Obes Metab; 2019 Jun; 21(6):1365-1372. PubMed ID: 30756511
[TBL] [Abstract][Full Text] [Related]
31. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis.
Mannucci E; Monami M; Marchionni N
Diabetes Obes Metab; 2009 Jan; 11(1):53-9. PubMed ID: 18671795
[TBL] [Abstract][Full Text] [Related]
32. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
[TBL] [Abstract][Full Text] [Related]
33. Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.
Monnier L; Colette C
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S9-6S15. PubMed ID: 26774019
[TBL] [Abstract][Full Text] [Related]
34. Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
Aronoff SL
Postgrad Med; 2017 Mar; 129(2):231-241. PubMed ID: 28118069
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
Kaneko K; Satake C; Izumi T; Tanaka M; Yamamoto J; Asai Y; Sawada S; Imai J; Yamada T; Katagiri H
BMC Endocr Disord; 2019 Jan; 19(1):5. PubMed ID: 30621663
[TBL] [Abstract][Full Text] [Related]
36. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus.
Kinsley B
Clin Ther; 2007; 29 Suppl D():S153-60. PubMed ID: 18191067
[TBL] [Abstract][Full Text] [Related]
37. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
Moses AC; Raskin P; Khutoryansky N
Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
[TBL] [Abstract][Full Text] [Related]
38. Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices.
Rathmann W; Kostev K
Diabetes Obes Metab; 2013 Apr; 15(4):358-63. PubMed ID: 23137345
[TBL] [Abstract][Full Text] [Related]
39. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Gerlach FM
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013228. PubMed ID: 30556900
[TBL] [Abstract][Full Text] [Related]
40. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Charpentier G; Riveline JP; Dardari D; Varroud-Vial M
Drugs; 2006; 66(3):273-86. PubMed ID: 16526817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
